Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Blueprint Medicines Corp. filings document the company’s biopharmaceutical issuer history, common stock registration, governance votes and corporate-status reporting. Recent Form 8-K disclosures include annual meeting matters such as director elections and advisory executive compensation votes, while Form 15 records the termination of registration or suspension of Exchange Act reporting duties for the company’s common stock.
The filing record also reflects capital-structure disclosure, stockholder voting procedures, registered-security information and material-event reporting associated with Blueprint Medicines’ public-company obligations.
Pentwater Capital Management LP and Matthew Halbower report beneficial ownership of 3,900,000 shares of Blueprint Medicines Corp common stock, representing 6.0% of the outstanding class based on 64,733,629 shares outstanding. The filing states the shares are directly held by the Pentwater Funds and that voting and dispositive power over these shares is shared (no sole voting or dispositive power reported). The Investment Manager is organized in Delaware and Mr. Halbower is a U.S. citizen; the business office for the reporting persons is 1001 10th Avenue South, Suite 216, Naples, FL. The statement certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing control.
T. Rowe Price Associates, Inc. filed Amendment No. 9 to a Schedule 13G disclosing its holdings in Blueprint Medicines Corp common stock. The filing reports an aggregate beneficial ownership of 1,465,036 shares, representing 2.3% of the class, with sole voting power of 1,429,561 shares and sole dispositive power of 1,459,988 shares. The statement affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The form is signed by Ellen York, Vice President, dated 08/14/2025.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 375,000 shares of Blueprint Medicines Corp common stock, equal to 0.6% of the class based on 64,733,629 shares outstanding as reported by the issuer. The filing shows both reporting persons have sole voting power and sole dispositive power for the reported shares. Avoro is identified as an investment adviser and Dr. Aghazadeh as the portfolio manager and controlling person; the shares are held for investment purposes on behalf of Avoro Life Sciences Fund LLC and are stated to be held in the ordinary course of business with no intent to change or influence control.